{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:22:06Z","timestamp":1787764926273,"version":"build-2784847793"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Vemurafenib is a selective BRAF-inhibitor that has been approved for the use in patients with advanced BRAF-mutant melanoma. Major adverse events include skin rash, photosensitivity, pruritus, cutaneous squamous-cell carcinoma or keratoacanthoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Observation:<\/jats:title>\n                    <jats:p>We present the case of a patient experiencing extensive sterile abscess of the scrotum after nine months of treatment with vemurafenib for oligometastatic (liver) BRAF-mutant melanoma. The scrotal lesion mimicked distant metastasis in a first round of clinical and radiological examinations, but was identified as sterile abscess after surgical exploration and complete excision. The patient went on to receive hemihepatectomy for melanoma supposedly confined to the liver, and continues receiving vemurafenib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>We describe a remarkable case of probably vemurafenib-related sterile abscess. This adverse event is of substantial clinical relevance, as it mimicks metastatic melanoma and requires careful diagnostic evaluation and proper treatment to allow a favorable patient outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0973-1482.136039","type":"journal-article","created":{"date-parts":[[2015,10,9]],"date-time":"2015-10-09T11:54:49Z","timestamp":1444391689000},"page":"647","source":"Crossref","is-referenced-by-count":3,"title":["Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis"],"prefix":"10.4103","volume":"11","author":[{"given":"Jennifer Gibbons","family":"Marsico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regulo","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"J\u00f6rger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-38-20231126","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R2-38-20231126","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.clinthera.2012.06.009","article-title":"Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma","volume":"34","author":"Ravnan","year":"2012","journal-title":"Clin Ther"},{"key":"R3-38-20231126","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/030089161209800506","article-title":"Metastatic melanoma: A regional review and future directions","volume":"98","author":"Khan","year":"2012","journal-title":"Tumori"},{"key":"R4-38-20231126","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-38-20231126","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R6-38-20231126","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jmoldx.2012.10.002","article-title":"Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma","volume":"15","author":"Greaves","year":"2013","journal-title":"J Mol Diagn"},{"key":"R7-38-20231126","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":"Prospective study of cutaneous side-effects associated with the BRAF-inhibitor vemurafenib: A stduy of 42 patients","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann Oncol"},{"key":"R8-38-20231126","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R9-38-20231126","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J Exp Med"},{"key":"R10-38-20231126","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1158\/1078-0432.CCR-10-1911","article-title":"The oncogenic BRAF kinase inhibitor PLX4032\/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations","volume":"16","author":"Comin-Anduix","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201511030-00038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:51:18Z","timestamp":1787763078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201511030-00038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.136039","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}